OncoCyte Corporation (NASDAQ:OCX) has a beta value of 1.88 and has seen 0.43 million shares traded in the last trading session. The company, currently valued at $388.29M, closed the last trade at $4.20 per share which meant it lost -$0.04 on the day or -0.94% during that session. The OCX stock price is -56.43% off its 52-week high price of $6.57 and 71.9% above the 52-week low of $1.18. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.43 million shares traded. The 3-month trading volume is 635.45K shares.
The consensus among analysts is that OncoCyte Corporation (OCX) is a Buy stock at the moment, with a recommendation rating of 1.80. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 6 have rated it as a Hold, with 6 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.1.
OncoCyte Corporation (NASDAQ:OCX) trade information
Sporting -0.94% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 09/03/21 when the OCX stock price touched $4.20 or saw a rise of 3.23%. Year-to-date, OncoCyte Corporation shares have moved 75.73%, while the 5-day performance has seen it change 0.00%. Over the past 30 days, the shares of OncoCyte Corporation (NASDAQ:OCX) have changed -13.58%. Short interest in the company has seen 3.04 million shares shorted with days to cover at 8.4.
Wall Street analysts have a consensus price target for the stock at $8.67, which means that the shares’ value could jump 51.56% from current levels. The projected low price target is $7.00 while the price target rests at a high of $11.00. In that case, then, we find that the current price level is -161.9% off the targeted high while a plunge would see the stock gain -66.67% from current levels.
OncoCyte Corporation (OCX) estimates and forecasts
Figures show that OncoCyte Corporation shares have outperformed across the wider relevant industry. The company’s shares have gained 14.44% over the past 6 months, with this year growth rate of 28.26%, compared to 18.10% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 28.60% and -20.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be 702.60%.
6 analysts offering their estimates for the company have set an average revenue estimate of $1.57 million for the current quarter. 6 have an estimated revenue figure of $1.96 million for the next quarter concluding in Sep 2021. Year-ago sales stood $143k and $370k respectively for this quarter and the next, and analysts expect sales will grow by 997.90% for the current quarter and 429.70% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.90% over the past 5 years.
OncoCyte Corporation is expected to release its next earnings report between November 10 and November 15 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
OncoCyte Corporation (NASDAQ:OCX)’s Major holders
Insiders own 10.33% of the company shares, while shares held by institutions stand at 62.89% with a share float percentage of 70.13%. Investors are also buoyed by the number of investors in a company, with OncoCyte Corporation having a total of 126 institutions that hold shares in the company. The top two institutional holders are Broadwood Capital, Inc. with over 16.78 million shares worth more than $96.3 million. As of Jun 29, 2021, Broadwood Capital, Inc. held 18.32% of shares outstanding.
The other major institutional holder is Pura Vida Investments, LLC, with the holding of over 12.22 million shares as of Jun 29, 2021. The firm’s total holdings are worth over $70.17 million and represent 13.35% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Mar 30, 2021, the former fund manager holds about 2.40% shares in the company for having 2.2 million shares of worth $11.39 million while later fund manager owns 1.61 million shares of worth $9.24 million as of Jun 29, 2021, which makes it owner of about 1.76% of company’s outstanding stock.